CLDN18 and gastric cancer: The loss of claudin-18 not only results in TJ dysfunction and lack of proton barrier properties but also leads to numerous pathologies including gastritis, chronic inflammation, and gastric cancer, therefore claudin-18 has been identified as a targeted therapy candidate [18,27,28,29,30].